Coronary Artery Disease Program
Coronary Artery Disease
Pre-clinicalActive
Key Facts
About Elixir Medical
Elixir Medical is an early-stage, private medical device company targeting the massive and underserved cardiovascular disease market. The company is developing transformative platforms for percutaneous coronary intervention (PCI) and peripheral interventions, aiming to address significant unmet needs such as high rates of adverse events and disease recurrence. While still in a pre-revenue, pre-clinical/development stage, Elixir positions itself as a disruptor seeking to reshape vascular medicine for decades to come by tackling problems where others have given up.
View full company profileTherapeutic Areas
Other Coronary Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| MUTI™ Drug‑Eluting Stent | Meril | Commercial |
| Coronary Artery Bypass Grafts | Vascudyne | Pre-clinical |
| Premier DES | Relisys Medical Devices | Commercial |
| Release R DES | Relisys Medical Devices | Commercial |
| Pristine DES | Relisys Medical Devices | Commercial |
| BioMatrix family (Flex/Alpha) | Biosensors International | Commercial |
| Essential pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| OMT-28 | OMEICOS Therapeutics | Phase 2 |
| Fantom Encore | REVA Medical | Commercial |
| Next-Gen Drug-Eluting Stents | Translumina | Development |
| Geographic Market Expansion | Translumina | Commercial |